PharmaMar Initiates a Phase III Registration Trial with Aplidin(R) in Multiple Myeloma Patients
Advertisement
PharmaMar SA (Grupo Zeltia) announced that a registration trial in relapsed/refractory multiple myeloma patients has been initiated with Aplidin(R) (plitidepsin) in combination with dexamethasone versus dexamethasone alone.
This pivotal, international, multicenter Phase III clinical trial, called ADMYRE, will enrol 300 patients in 60 medical centers across 20 countries (including the U.S., Europe, Asia and South America), with an estimated recruitment period of 24 months. The primary objective of ADMYRE is Progression Free Survival (PFS).
Aplidin(R) is an anti-tumor agent originally isolated from the Mediterranean tunicate Aplidium albicans and currently obtained by chemical synthesis. Aplidin(R) is the second most advanced compound in clinical development at PharmaMar.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
European Commission approves update of Erbitux
Nanozymes - efficient antidote against pesticides
Category:Genes_on_chromosome_13
BioSpring and Phenion receive BMBF-Funding for the development of a bioactive for skin treatment
Fisher Biosciences unit, Cellomics, and Evotec Technologies Sign License Agreement - Companies to collaborate on cell-biology solutions for life-science markets
Celera:Carriers of a Gene Variant are at Elevated risk of Coronary Heart Disease Which is Virtually Eliminated by Statin Therapy - New studies in more than 30,000 individuals indicate that carriers of the KIF6 gene variant have up to a 55% increased risk of a coronary event
Scientists have discovered how to predict life of implants without animal testing
Baxter and Cerus Halt Red Blood Cell Clinical Trials for Investigational Pathogen Inactivation System
UofL receives Bill and Melinda Gates Foundation Grand Challenges TB biomarkers grant
Nottinghamshire_Deaf_Society
In lab research, scientists limit autistic behavior
